MedTrace Logo

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

NCT03420430 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-09-25

No results posted yet for this study

Summary

GL-ONC1 expanded access is for patients who are ineligible for an ongoing GL-ONC1 clinical trial. Expanded access is intended to treat individual patients with advanced stage cancers, including blood cancer, with no standard of care options for treatment. Potential patients will be evaluated individually depending on GL-ONC1 product supply.

Conditions

  • Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)
  • Acute Myeloid Leukemia (6 Patients)

Interventions

BIOLOGICAL

GL-ONC1

Sponsors & Collaborators

  • Genelux Corporation

    lead INDUSTRY

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03420430 on ClinicalTrials.gov